跳转至内容
Merck
CN

主要文件

查看所有文档

V900339

胞嘧啶 β-D-呋喃阿拉伯糖苷

Vetec™, reagent grade, 90%

别名:

(β-D-阿拉伯呋喃糖基)胞嘧啶, Ara-C, 胞嘧啶阿拉伯糖苷, 阿拉伯糖胞嘧啶, 阿糖胞嘧啶, 阿糖胞苷

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C9H13N3O5
化学文摘社编号:
147-94-4
分子量:
243.22
EC Number:
205-705-9
UNSPSC Code:
12352200
PubChem Substance ID:
329829757
Beilstein/REAXYS Number:
89175
MDL number:
MFCD00066487
Assay:
90%
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

grade

reagent grade

product line

Vetec™

assay

90%

storage temp.

2-8°C

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

InChI key

UHDGCWIWMRVCDJ-CCXZUQQUSA-N

Gene Information

human ... POLA1(5422), POLA2(23649), POLD1(5424), POLD2(5425), POLD3(10714), POLD4(57804), POLE(5426), POLE2(5427), POLE3(54107), PRIM1(5557), PRIM2(5558)

Biochem/physiol Actions

阿糖胞苷复合到 DNA 中后，可通过与导致 DNA 断裂的拓扑异构酶 I 形成可裂解复合物而抑制 DNA 的复制，但不会抑制 RNA 的合成。抗白血病制剂。

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Muta. 1B - Repr. 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
WXBF3616V
WXBD4127V
WXBB1867V
SLBB7404V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jorge Cortes et al.
The Lancet. Oncology, 14(4), 354-362 (2013-03-05)
Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). We aimed to compare two dosing regimens of tosedostat. In this randomised phase
Julie M Vose et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(13), 1662-1668 (2013-03-13)
This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients with chemotherapy-sensitive persistent or relapsed DLBCL were
Sergio Amadori et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4424-4430 (2013-10-16)
This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients (n = 472) age 61 to 75 years were randomly assigned to induction
查看所有相关文献

全球贸易项目编号

货号GTIN
V900339-1G04061826740019